KRAS and gastric cancer: For instance, CSNK2A1 promotes gastric cancer invasiveness via the PI3K-Akt-mTOR signal pathway; CSNK2A1 is a mediator of MEK/ERK inhibitor resistance in KRAS (G12C) mutant LC cells [52]; CSNK2A1 is a promising new prognostic marker for renal cell carcinoma [53].